Patents by Inventor Jeremy Loyau

Jeremy Loyau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES THAT BIND TO IL1RAP AND USES THEREOF
    Publication number: 20240327530
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and my also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 3, 2024
    Inventors: Julie MACOIN, Amelie CROSET, Jeremy LOYAU, Thierry MONNEY, Lamine MBOW, Marie-Agnes DOUCEY, Valentina LABANCA
  • ANTIBODIES THAT BIND TO IL1RAP AND USES THEREOF
    Publication number: 20240327531
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and my also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 3, 2024
    Inventors: Julie MACOIN, Amelie CROSET, Jeremy LOYAU, Thierry MONNEY, Lamine MBOW, Marie-Agnes DOUCEY, Valentina LABANCA
  • CD3/BCMA/CD38 Trispecific Antibodies
    Publication number: 20240228650
    Abstract: The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.
    Type: Application
    Filed: May 4, 2023
    Publication date: July 11, 2024
    Inventors: Maria PIHLGREN BOSCH, Mario PERRO, Olivia HALL, Laura CARRETERO IGLESIA, Adam DRAKE, Daniela PAIS, Rebecca CROASDALE-WOOD, Jérémy LOYAU, Carole ESTOPPEY, Ankita SRIVASTAVA, Michael DYSON, Julie MACOIN, Myriam CHIMEN, Thierry MONNEY, Cyrille DREYFUS
  • CD47-CD38 BISPECIFIC ANTIBODIES
    Publication number: 20240150489
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Application
    Filed: October 11, 2023
    Publication date: May 9, 2024
    Inventors: Laure BOUCHEZ, Blandine POULEAU, Marie-Agnes DOUCEY, Elie DHEILLY, Stanislas BLEIN, Cian STUTZ, Carole ESTOPPEY, Jeremy LOYAU, Thierry MONNEY, Camille GRANDCLEMENT, Stefano SAMMICHELI
  • CD47-CD38 BISPECIFIC ANTIBODIES
    Publication number: 20240141062
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Application
    Filed: October 11, 2023
    Publication date: May 2, 2024
    Inventors: Laure BOUCHEZ, Blandine POULEAU, Marie-Agnes DOUCEY, Elie DHEILLY, Stanislas BLEIN, Cian STUTZ, Carole ESTOPPEY, Jeremy LOYAU, Thierry MONNEY, Camille GRANDCLEMENT, Stefano SAMMICHELI, Cyrille DREYFUS
  • Antibodies that bind to IL1RAP and uses thereof
    Patent number: 11970539
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and may also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: April 30, 2024
    Assignee: Ichnos Sciences SA
    Inventors: Julie Macoin, Amelie Croset, Jeremy Loyau, Thierry Monney, Lamine Mbow, Marie-Agnes Doucey, Valentina Labanca
  • CD3/BCMA/CD38 Trispecific Antibodies
    Publication number: 20240132615
    Abstract: The present invention relates to novel trispecific heterodimeric immunoglobulins. More specifically the present invention relates to trispecific heterodimeric immunoglobulins that target human CD3 antigen, human BCMA and human CD38 antigen. The present invention also relates to this novel class of trispecific heterodimeric immunoglobulins for use in the treatment of proliferative diseases and in particular cancers such as hematological cancer. The present invention relates to novel trispecific antibody for use in treating multiple myeloma.
    Type: Application
    Filed: May 3, 2023
    Publication date: April 25, 2024
    Inventors: Maria PIHLGREN BOSCH, Mario PERRO, Olivia HALL, Laura CARRETERO IGLESIA, Adam DRAKE, Daniela PAIS, Rebecca CROASDALE-WOOD, Jérémy LOYAU, Carole ESTOPPEY, Ankita SRIVASTAVA, Michael DYSON, Julie MACOIN, Myriam CHIMEN, Thierry MONNEY, Cyrille DREYFUS
  • ANTI-TLR4 ANTIBODIES AND USES THEREOF
    Publication number: 20220324994
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Application
    Filed: November 15, 2021
    Publication date: October 13, 2022
    Inventors: Francois ROUSSEAU, Jeremy LOYAU, Nicolas FISCHER, Greg ELSON, Marie KOSCO-VILBOIS
  • ANTIBODIES THAT BIND TO IL1RAP AND USES THEREOF
    Publication number: 20220089754
    Abstract: The present invention relates to antibodies which specifically bind to human IL1RAP and my also bind to cynomolgus monkey and/or mouse IL1RAP. The present invention also relates to the use of such antibodies to diagnose and treat human disease.
    Type: Application
    Filed: September 14, 2021
    Publication date: March 24, 2022
    Inventors: Julie MACOIN, Amelie CROSET, Jeremy LOYAU, Thierry MONNEY, Lamine MBOW, Marie-Agnes DOUCEY, Valentina LABANCA
  • CD47-CD38 BISPECIFIC ANTIBODIES
    Publication number: 20220089767
    Abstract: Novel bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and human CD38 antigen are provided and in particular those comprising an anti-CD38 heavy chain variable region and a light chain variable region and an anti-CD47 heavy chain variable region and a light chain variable region. The present invention also relates to the use of this novel class of bispecific heterodimeric immunoglobulins to treat autoimmune and proliferative diseases and in particular cancers such as hematologic malignancies and solid tumors.
    Type: Application
    Filed: September 17, 2021
    Publication date: March 24, 2022
    Inventors: Laure Bouchez, Blandine Pouleau, Marie-Agnes Doucey, Elie Dheilly, Stanislas Blein, Cian Stutz, Carole Estoppey, Jeremy Loyau, Thierry Monney, Camille Grandclement, Stefano Sammicheli
  • Anti-TLR4 antibodies and uses thereof
    Patent number: 10982004
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: April 20, 2021
    Assignee: NovImmune SA
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois
  • ANTI-TLR4 ANTIBODIES AND USES THEREOF
    Publication number: 20200207866
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Application
    Filed: July 19, 2019
    Publication date: July 2, 2020
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois
  • Antibodies that bind to CCR6 and their uses
    Patent number: 10640564
    Abstract: The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: May 5, 2020
    Assignee: Ichnos Sciences SA
    Inventors: Rami Lissilaa, Adrian Walmsley, Stanislas Blein, Romain Ollier, Samuel Hou, Jeremy Loyau
  • Anti-TLR4 antibodies and uses thereof
    Patent number: 10400044
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: September 3, 2019
    Assignee: NovImmune SA
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois
  • ANTIBODIES THAT BIND TO CCR6 AND THEIR USES
    Publication number: 20180086836
    Abstract: The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.
    Type: Application
    Filed: October 19, 2015
    Publication date: March 29, 2018
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Rami LISSILAA, Adrian WALMSLEY, Stanislas BLEIN, Romain OLLIER, Samuel HOU, Jeremy LOYAU
  • ANTI-TLR4 ANTIBODIES AND USES THEREOF
    Publication number: 20170008967
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Application
    Filed: September 26, 2016
    Publication date: January 12, 2017
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois
  • Anti-TLR4 antibodies and uses thereof
    Patent number: 9453076
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: September 27, 2016
    Assignee: NOVIMMUNE S.A.
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois
  • Anti-TLR4 Antibodies and Uses Thereof
    Publication number: 20130315914
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Application
    Filed: March 29, 2013
    Publication date: November 28, 2013
    Applicant: NovImmune S.A.
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois